Bone · Research Phase
Calcitonin Gene-Related Peptide (CGRP)
No lawful US pathway
01 · Overview
Calcitonin gene-related peptide is a neuropeptide produced by alternative splicing of the calcitonin gene, with CGRP-alpha and CGRP-beta isoforms. It is a potent vasodilator and a central mediator in migraine, and it is also present in peptidergic sensory nerve fibers innervating bone and periosteum, where it is described as an osteoanabolic neurotransmitter (PMID 25536054).
Therapeutic development has focused on blocking CGRP signaling rather than on administering the peptide. CGRP itself is not an approved therapy for bone or any other indication.
02 · Research summary & key findings
Gepants, which are selective CGRP receptor antagonists, and monoclonal antibodies targeting CGRP or its receptor have established efficacy over placebo in phase 3 migraine prevention trials, with generally better tolerability than traditional preventives (PMID 40447296). Evidence for direct skeletal effects of CGRP comes mainly from rodent work, such as mechanical loading studies in CGRP-alpha and CGRP-beta knockout mice used to test whether CGRP signaling is required for normal adaptive bone modeling (PMID 25536054). No clinical evidence supports exogenous CGRP administration for bone disorders.
03 · Regulatory status
Calcitonin Gene-Related Peptide (CGRP) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
No lawful pathway today
Calcitonin Gene-Related Peptide (CGRP) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 8 FDA-approved compounds in Bone
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for injury recovery and tissue repair?
Calcitonin Gene-Related Peptide (CGRP) is a research compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on injury recovery and tissue repair, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Intravenous
- Subcutaneous injection
References
- [1]Role of calcitonin gene-related peptide in functional adaptation of the skeleton PLoS One, 2014. PMID 25536054
- [2]Repurposed versus disease-specific medicinals for the prophylaxis of migraine: an updated systematic review Pain Manag, 2025. PMID 40447296
Primary literature
- PubMed: "Calcitonin Gene-Related Peptide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Calcitonin Gene-Related Peptide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Calcitonin Gene-Related Peptide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Bone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.